BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 16966094)

  • 41. Aryl hydrocarbon receptor knockout rats are insensitive to the pathological effects of repeated oral exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Harrill JA; Layko D; Nyska A; Hukkanen RR; Manno RA; Grassetti A; Lawson M; Martin G; Budinsky RA; Rowlands JC; Thomas RS
    J Appl Toxicol; 2016 Jun; 36(6):802-14. PubMed ID: 26278112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactive effects between 2,3,7,8-tetrachlorodibenzo-p-dioxin and 2,2',4,4',5,5'-hexachlorobiphenyl in female B6C3F1 mice: tissue distribution and tissue-specific enzyme induction.
    van Birgelen AP; Ross DG; DeVito MJ; Birnbaum LS
    Fundam Appl Toxicol; 1996 Nov; 34(1):118-31. PubMed ID: 8937899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Area under the curve as a dose metric for promotional responses following 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure.
    Kim AH; Kohn MC; Nyska A; Walker NJ
    Toxicol Appl Pharmacol; 2003 Aug; 191(1):12-21. PubMed ID: 12915100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the use of a physiologically based pharmacokinetic model and a classical pharmacokinetic model for dioxin exposure assessments.
    Emond C; Michalek JE; Birnbaum LS; DeVito MJ
    Environ Health Perspect; 2005 Dec; 113(12):1666-8. PubMed ID: 16330344
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of TCDD and PCB CYP1A induction sensitivities in fresh hepatocytes from human donors, sprague-dawley rats, and rhesus monkeys and HepG2 cells.
    Silkworth JB; Koganti A; Illouz K; Possolo A; Zhao M; Hamilton SB
    Toxicol Sci; 2005 Oct; 87(2):508-19. PubMed ID: 16049271
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Smith AG; Clothier B; Carthew P; Childs NL; Sinclair PR; Nebert DW; Dalton TP
    Toxicol Appl Pharmacol; 2001 Jun; 173(2):89-98. PubMed ID: 11384210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The toxicological significance of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds in human adipose tissue.
    Byard JL
    J Toxicol Environ Health; 1987; 22(4):381-403. PubMed ID: 3694702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and 1,2,3,4,7,8-hexachlorodibenzo-p-dioxin (HxCDD) alter body weight by decreasing insulin-like growth factor I (IGF-I) signaling.
    Croutch CR; Lebofsky M; Schramm KW; Terranova PF; Rozman KK
    Toxicol Sci; 2005 May; 85(1):560-71. PubMed ID: 15703265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytochrome P450 1A2 activity and incidence of thyroid disease and cancer after chronic or acute exposure to dioxins.
    Samer CF; Gloor Y; Rollason V; Guessous I; Doffey-Lazeyras F; Saurat JH; Sorg O; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):296-303. PubMed ID: 31608602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physiologically based toxicokinetic models and in silico predicted partition coefficients to estimate tetrachlorodibenzo-p-dioxin transfer from feed into growing pigs.
    Savvateeva D; Numata J; Pieper R; Schafft H; Lahrssen-Wiederholt M; Bulik S
    Arch Toxicol; 2020 Jan; 94(1):187-196. PubMed ID: 31728592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of chlorinated hydrocarbons on expression of cytochrome P450 1A1, 1A2 and 1B1 and 2- and 4-hydroxylation of 17beta-estradiol in female Sprague-Dawley rats.
    Badawi AF; Cavalieri EL; Rogan EG
    Carcinogenesis; 2000 Aug; 21(8):1593-9. PubMed ID: 10910964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulation of CYP1A2 by histone deacetylase inhibitors in mouse hepatocytes.
    Jin B; Ryu DY
    J Biochem Mol Toxicol; 2004; 18(3):131-2. PubMed ID: 15252868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and congeners in infants. A toxicokinetic model of human lifetime body burden by TCDD with special emphasis on its uptake by nutrition.
    Kreuzer PE; Csanády GA; Baur C; Kessler W; Päpke O; Greim H; Filser JG
    Arch Toxicol; 1997; 71(6):383-400. PubMed ID: 9195020
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationships between tissue levels of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), mRNAs, and toxicity in the developing male Wistar(Han) rat.
    Bell DR; Clode S; Fan MQ; Fernandes A; Foster PM; Jiang T; Loizou G; MacNicoll A; Miller BG; Rose M; Tran L; White S
    Toxicol Sci; 2007 Oct; 99(2):591-604. PubMed ID: 17656490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between CYP1A enzyme activities and protein levels in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    DeVito MJ; Beebe LE; Menache M; Birnbaum LS
    J Toxicol Environ Health; 1996 Mar; 47(4):379-94. PubMed ID: 8600290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses.
    Kim AH; Kohn MC; Portier CJ; Walker NJ
    Regul Toxicol Pharmacol; 2002 Dec; 36(3):287-96. PubMed ID: 12473413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of human and rat CYP1A2 by TCDD and dioxin-like chemicals.
    Staskal DF; Diliberto JJ; Devito MJ; Birnbaum LS
    Toxicol Sci; 2005 Apr; 84(2):225-31. PubMed ID: 15659567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.
    Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ
    Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative potency based on hepatic enzyme induction predicts immunosuppressive effects of a mixture of PCDDS/PCDFS and PCBS.
    Smialowicz RJ; DeVito MJ; Williams WC; Birnbaum LS
    Toxicol Appl Pharmacol; 2008 Mar; 227(3):477-84. PubMed ID: 18190939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.